{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:09:58Z","timestamp":1791216598276,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00415-020-10007-1","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T16:03:23Z","timestamp":1593014603000},"page":"3337-3342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Use of diffusion-weighted imaging to distinguish seizure-related change from limbic encephalitis"],"prefix":"10.1007","volume":"267","author":[{"given":"Adrian","family":"Budhram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0147-8159","authenticated-orcid":false,"given":"Jeffrey W.","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta B.","family":"Liebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyanshu","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Zekeridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McKeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri A.","family":"Braksick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L.","family":"Zalewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"issue":"4","key":"10007_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15(4):391\u2013404","journal-title":"Lancet Neurol"},{"issue":"9","key":"10007_CR2","first-page":"1377","volume":"60","author":"FC Chow","year":"2015","unstructured":"Chow FC, Glaser CA, Sheriff H, Xia D, Messenger S, Whitley R et al (2015) Use of clinical and neuroimaging characteristics to distinguish temporal lobe herpes simplex encephalitis from its mimics. Clin Infect Dis 60(9):1377\u20131383","journal-title":"Clin Infect Dis"},{"issue":"19","key":"10007_CR3","doi-asserted-by":"publisher","first-page":"E529","DOI":"10.1503\/cmaj.181548","volume":"191","author":"A Budhram","year":"2019","unstructured":"Budhram A, Leung A, Nicolle MW, Burneo JG (2019) Diagnosing autoimmune limbic encephalitis. CMAJ 191(19):E529\u2013E534","journal-title":"CMAJ"},{"issue":"3","key":"10007_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00415-018-8767-1","volume":"265","author":"A Vogrig","year":"2018","unstructured":"Vogrig A, Joubert B, Ducray F, Thomas L, Izquierdo C, Decaestecker K et al (2018) Glioblastoma as differential diagnosis of autoimmune encephalitis. J Neurol 265(3):669\u2013677","journal-title":"J Neurol"},{"key":"10007_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.seizure.2017.04.005","volume":"48","author":"SE Kim","year":"2017","unstructured":"Kim SE, Lee BI, Shin KJ, Ha SY, Park J, Park KM et al (2017) Characteristics of seizure-induced signal changes on MRI in patients with first seizures. Seizure 48:62\u201368","journal-title":"Seizure"},{"key":"10007_CR6","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.3389\/fimmu.2018.02708","volume":"9","author":"S Macher","year":"2018","unstructured":"Macher S, Zimprich F, De Simoni D, Hoftberger R, Rommer PS (2018) Management of autoimmune encephalitis: an observational monocentric study of 38 patients. Front Immunol 9:2708","journal-title":"Front Immunol"},{"issue":"6","key":"10007_CR7","first-page":"1149","volume":"22","author":"JA Kim","year":"2001","unstructured":"Kim JA, Chung JI, Yoon PH, Kim DI, Chung TS, Kim EJ et al (2001) Transient MR signal changes in patients with generalized tonicoclonic seizure or status epilepticus: periictal diffusion-weighted imaging. AJNR 22(6):1149\u20131160","journal-title":"AJNR"},{"issue":"1\u20132","key":"10007_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eplepsyres.2011.07.002","volume":"97","author":"A Chatzikonstantinou","year":"2011","unstructured":"Chatzikonstantinou A, Gass A, Forster A, Hennerici MG, Szabo K (2011) Features of acute DWI abnormalities related to status epilepticus. Epilepsy Res 97(1\u20132):45\u201351","journal-title":"Epilepsy Res"},{"issue":"Pt 6","key":"10007_CR9","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1093\/brain\/awh454","volume":"128","author":"K Szabo","year":"2005","unstructured":"Szabo K, Poepel A, Pohlmann-Eden B, Hirsch J, Back T, Sedlaczek O et al (2005) Diffusion-weighted and perfusion MRI demonstrates parenchymal changes in complex partial status epilepticus. Brain 128(Pt 6):1369\u20131376","journal-title":"Brain"},{"issue":"2","key":"10007_CR10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/mus.25027","volume":"54","author":"NL Zalewski","year":"2016","unstructured":"Zalewski NL, Lennon VA, Lachance DH, Klein CJ, Pittock SJ, McKeon A (2016) P\/Q- and N-type calcium-channel antibodies: oncological, neurological, and serological accompaniments. Muscle Nerve 54(2):220\u2013227","journal-title":"Muscle Nerve"},{"issue":"1","key":"10007_CR11","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ana.25131","volume":"83","author":"D Dubey","year":"2018","unstructured":"Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA et al (2018) Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 83(1):166\u2013177","journal-title":"Ann Neurol"},{"key":"10007_CR12","doi-asserted-by":"crossref","unstructured":"L\u00f3pez Chiriboga AS, Siegel JL, Tatum WO, Shih JJ, Flanagan EP (2017) Striking basal ganglia imaging abnormalities in LGI1 ab faciobrachial dystonic seizures. Neurol (R) Neuroimmunol Neuroinflamm 4(3):e336","DOI":"10.1212\/NXI.0000000000000336"},{"issue":"1","key":"10007_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3174\/ajnr.A3633","volume":"35","author":"AL Kotsenas","year":"2014","unstructured":"Kotsenas AL, Watson RE, Pittock SJ, Britton JW, Hoye SL, Quek AM et al (2014) MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis. AJNR 35(1):84\u201389","journal-title":"AJNR"},{"issue":"5","key":"10007_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0895-6111(01)00005-2","volume":"25","author":"RN Sener","year":"2001","unstructured":"Sener RN (2001) Herpes simplex encephalitis: diffusion MR imaging findings. Compute Med Imaging Gr 25(5):391\u2013397","journal-title":"Compute Med Imaging Gr"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10007-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-10007-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10007-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:58:59Z","timestamp":1624496339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-10007-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10007"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-10007-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"10 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Adrian Budhram has no disclosures to report. Dr. Jeff Britton is a consultant for UCB pharmaceuticals, investigational drug discussion, Rozanolixizumab; a co-investigator, unpaid, for GW Pharma in a double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experience inadequately-controlled seizures; a co-investigator, unpaid, for Grifols Pharmaceuticals in a Randomized Double-Blind Placebo Controlled Study of IVIG in Patients with Voltage-Gated Potassium Channel Complex Antibody Associated Autoimmune Epilepsy. Dr. Greta Liebo has no disclosures to report. Dr. Divyanshu Dubey has a patent pending for Kelch-like protein 11 as a marker of neurological autoimmunity and has received research support from Grifols, Translational Research Innovation and Test Development Office and, Center for Clinical and Translational Science. Dr. Dubey has consulted for UCB and Astellas. All compensation for consulting activities is paid directly to Mayo Clinic. Dr. Anastasia Zekeridou has a patent pending on PDE10A-IgG as a biomarker of neurological autoimmunity. Dr. Eoin Flanagan is a site principal investigator in a randomized placebo-controlled clinical trial of Inebilizumab (A CD19 inhibitor) in neuromyelitis optica spectrum disorders funded by MedImmune\/Viela Bio. He receives no personal compensation and just receives reimbursement for the research activities related to the trial. Dr. Andrew McKeon reports grants from Alexion, grants from Grifols, grants from Euroimmun, outside the submitted work; in addition, Dr. McKeon has a patent Septin-5-IgG pending, a patent PDE10A-IgG pending, a patent MAP1B-IgG pending, and a patent GFAP-IgG pending. Dr. Sean Pittock reports grants, personal fees and non-financial support from Alexion Pharmaceuticals, Inc.; grants from Grifols, Autoimmune Encephalitis Alliance; grants, personal fees, non-financial support and other from MedImmune, Inc.;\u00a0Dr. Pittock has a patent # 9,891,219 (Application#12-573942) \u201cMethods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive\u201d. Dr Pittock also has patents pending for the following IgGs as biomarkers of autoimmune neurological disorders (septin-5, Kelch-like protein 11, GFAP, PDE10A and MAP1B). Dr. Sherri Braksick has no disclosures to report. Dr. Nicholas Zalewski has no disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The Mayo Clinic Institutional Review Board (IRB) approved the study (IRB number 08\u2010006647).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As patients were identified retrospectively informed consent was not specifically obtained for this submission, but the patients did agree to use of their medical records for research purposes and no patient-identifying images have been included.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors consent to the publication of this manuscript. The manuscript and figures have not been published or copyrighted elsewhere.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}